Machine learning models for dementia screening to classify brain amyloid positivity on positron emission tomography using blood markers and demographic characteristics: a retrospective observational study

Alzheimers Res Ther. 2025 Jan 21;17(1):25. doi: 10.1186/s13195-024-01650-1.

Abstract

Background: Intracerebral amyloid β (Aβ) accumulation is considered the initial observable event in the pathological process of Alzheimer's disease (AD). Efficient screening for amyloid pathology is critical for identifying patients for early treatment. This study developed machine learning models to classify positron emission tomography (PET) Aβ-positivity in participants with preclinical and prodromal AD using data accessible to primary care physicians.

Methods: This retrospective observational study assessed the classification performance of combinations of demographic characteristics, routine blood test results, and cognitive test scores to classify PET Aβ-positivity using machine learning. Participants with mild cognitive impairment (MCI) or normal cognitive function who visited Oita University Hospital or had participated in the USUKI study and met the study eligibility criteria were included. The primary endpoint was assessment of the classification performance of the presence or absence of intracerebral Aβ accumulation using five machine learning models (i.e., five combinations of variables), each constructed with three classification algorithms, resulting in a total of 15 patterns. L2-regularized logistic regression, and kernel Support Vector Machine (SVM) and Elastic Net algorithms were used to construct the classification models using 34 pre-selected variables (12 demographic characteristics, 11 blood test results, 11 cognitive test results).

Results: Data from 262 records (260 unique participants) were analyzed. The mean (standard deviation [SD]) participant age was 73.8 (7.8) years. Using L2-regularized logistic regression, the mean receiver operating characteristic (ROC) area under the curve (AUC) (SD) in Model 0 (basic demographic characteristics) was 0.67 (0.01). Classification performance was similar in Model 1 (basic demographic characteristics and Mini Mental State Examination [MMSE] subscores) and Model 2 (demographic characteristics and blood test results) with a cross-validated mean ROC AUC (SD) of 0.70 (0.01) for both. Model 3 (demographic characteristics, blood test results, MMSE subscores) and Model 4 (Model 3 and ApoE4 phenotype) showed improved performance with a mean ROC AUC (SD) of 0.73 (0.01) and 0.76 (0.01), respectively. In models using blood test results, thyroid-stimulating hormone and mean corpuscular volume tended to be the largest contributors to classification. Classification performances were similar using the SVM and Elastic Net algorithms.

Conclusions: The machine learning models used in this study were useful for classifying PET Aβ-positivity using data from routine physician visits.

Trial registration: UMIN Clinical Trials Registry (UMIN000051776, registered on 31/08/2023).

Keywords: AD; Alzheimer’s disease; Amyloid β positivity; Dementia; Machine learning.

Publication types

  • Observational Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / blood
  • Alzheimer Disease / diagnostic imaging
  • Amyloid beta-Peptides / blood
  • Amyloid beta-Peptides / metabolism
  • Biomarkers / blood
  • Brain* / diagnostic imaging
  • Brain* / metabolism
  • Cognitive Dysfunction / blood
  • Cognitive Dysfunction / diagnosis
  • Cognitive Dysfunction / diagnostic imaging
  • Dementia / blood
  • Dementia / diagnosis
  • Dementia / diagnostic imaging
  • Female
  • Humans
  • Machine Learning*
  • Male
  • Middle Aged
  • Positron-Emission Tomography* / methods
  • Retrospective Studies

Substances

  • Biomarkers
  • Amyloid beta-Peptides